Clinical trial
Tailored Exercise Training Study Among Adults With HFpEF
Recruiting now · Phase 2, Phase 3 · 1 countries · Registry ID NCT07223242
What this study is about
Heart failure with preserved ejection fraction (HFpEF) is associated with a high morbidity and mortality burden. There are limited pharmacological options available for the treatment of HFpEF. Exercise intolerance (EI) is the cardinal symptom of HFpEF, which manifests as dyspnea and fatigue. EI leads to functional deconditioning and reduced quality of life (QOL), both of which elevate risk of death and hospitalization in patients with HFpEF. Supervised exercised training is associated with improvements in exercise capacity and QOL in adults with HFpEF. However, supervised exercise has not been widely utilized for the treatment of HFpEF due to logistical and fiscal barriers. This study will investigate the effects of a remote exercise training intervention on exercise capacity and skeletal muscle composition in patients with HFpEF, or those at risk for it. In addition, it will compare four different lifestyle interventions for their effects on exercise capacity.
Basic eligibility
Full registry criteria
Treatments and study arms
Moderate-intensity continuous training (MCT)
Tailored moderate-intensity exercise training video with weekly virtual meetings with a coach
Resistance training
Resistance training videos assigned to patient
Weight loss
Initiation/intensification of weight loss medications, such as semaglutide or tirzepatide
Primary outcomes
VO2peak indexed to body weight (mL/kg/min) will be the co-primary outcome for the trial. VO2peak is a gold-standard measure of aerobic exercise capacity and will be measured by maximal exercise test using a previously established ergometer protocol
SPPB will be a co-primary outcome for the trial. Score ranges from 0 to 12, with 0 indicating the worst performance and 12 indicating the best.
Study locations
1 locations were listed when this page was built. The first 40 are shown.